Genitourinary Cancer—Kidney and Bladder

Brian I. Rini, Elizabeth R. Plimack, Viktor Stus, et al.
The study authors present the longest follow-up of an anti-PD–1/L1 immunotherapy combined with a VEGF/VEGFR inhibitor for first-line RCC (median follow-up of 42.8 mo). Pembrolizumab + axiitinib continues to demonstrate superior efficacy over sunitinib with respect to OS, PFS, and ORR. No new safety signals were observed. Clinical trial information: NCT02853331
Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, et al.
The study authors demonstrated, that the addition of telaglenastat - an investigational, first-in-class, selective, oral GLS inhibitor that blocks glutamine utilization and critical downstream pathways - did not improve the efficacy of cabozantinb in mRCC. The combination was well tolerated and the adverse events were consistent with known risks of both agents. Clinical trial information: NCT03428217
Robert J. Motzer, Camillo Porta, Boris Alekseev,  et al.
The study authors conclude, that compared with sunitinib, patients in lenvatinib + pembrolizumab group had similar or better symptoms and health-related quality-of-life. Clinical trial information: NCT02811861
Matt D. Galsky, Siamak Daneshmand, Kevin G. Chan, et al.
The study authors conclude, that the transurethral resection of bladder tumor + gemcitabine, cisplatin, plus nivolumab achieves stringently defined cCR in a large subset of patients with MIBC. 1-year bladder intact survival is possible through the durability of responses. The role of genomic biomarkers in management algorithms requires longer follow-up. Clinical trial information: NCT03558087
Arjun Vasant Balar, Matthew I. Milowsky, Peter H. O'Donnell, et al.
The study authors conclude, that pembrolizumab added to hypofractionated RT and twice-weekly gem was well-tolerated. A promising efficacy was observed in this early analysis. Pembrolizumab-related toxicity did not differ from prior monotherapy trials. Clinical trial information: NCT02621151
Xavier Garcia del Muro, Begoña P. Valderrama, Ana Medina, et al.
The study authors conclude, that a combined-modality approach including durvalumab + tremelimumab with concurrent radiotherapy is feasible and safe. The treatment is showing high efficacy in terms of response and eliciting bladder preservation in a large number of patients. Clinical trial information: NCT03702179
Sumanta K. Pal, Amir Mortazavi, Matthew I. Milowsky, et al.
The study authors oberved no improvement in progression-free survival with the addition of berzosertib to cisplatin with gemcitabine. Also a trend towards inferior survival was observed. Caution is suggested in reducing the starting dose of cytotoxic therapy to accommodate the addition of a myelosuppressive agent, as in the experimental arm of this study. Clinical trial information: NCT02567409
Peter H. O'Donnell, Arjun Vasant Balar, Jacqueline Vuky, et al.
The study authors conclude, that after up to 5 y of follow-up, pembrolizumab continued to elicit clinically meaningful, durable antitumor activity in cisplatin-ineligible patients with advanced UC - and more pronounced in patients with combined positive score ≥10 (CPS, number of PD-L1–staining cells [tumor cells, lymphocytes, macrophages] divided by the total number of viable tumor cells, multiplied by 100). Clinical trial information: NCT02335424
Arjun Vasant Balar, Victor Moreno, Eric Angevin, et al.
The study authors present results with feladilimab, the first Inducible T-cell co-stimulatory (ICOS) receptor agonist with reported single-agent activity in anti-PD-1/L1–exp relapsed/refractory UC. The combination with feladilimab and pembrolizumab shows promising clinical activity and manageable safety in PD-1/L1–naïve R/M UC.Clinical trial information: NCT02723955